⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AdvantiGen Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AdvantiGen Biosciences
↗Madison, WI, United States
AdvantiGen Biosciences is a biotechnology company focused on developing next-generation immunotherapies for cancer and inflammation. The company specializes in targeting sialic-acid-binding immunoglobulin-like lectin 5 (Siglec-5) on activated T-cells using monoclonal antibodies and its proprietary NIRID™ (Near InfraRed Identification and Detection) technology.
By modulating the interaction between this novel immune checkpoint target and its ligands, AdvantiGen aims to restore the ability of T-cells to eliminate cancer cells. Their therapeutic approach is being evaluated for both solid tumors—including skin, kidney, breast, colorectal, lung, and liver cancers—and blood cancers such as T-cell lymphoma and acute monocytic leukemia.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0.5M-$1.7M
Founded:2015
Ownership:private
Status:operating
FUNDING
Total Raised:$0
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:mAb, Monobodies
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Various research and distributor partners for drug discovery and diagnostic development
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Pascal Longchamp - Chief Executive Officer
Howard Teeter - Chief Financial Officer
Heather Kirkpatrick - Chief Business Officer
Andrew Ulijasz - Chief Scientific Officer
Scientific Founders:Andrew Ulijasz, Mark Jackson
LINKS
Website:advantigenbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AdvantiGen Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.